⚕ GalenOps CRO console
← SITE008 (KOR)

SITE008-0290

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE008 (KOR) (Dr. Kim) · consented 2023-02-04
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

severe assessed 2026-08-18

Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-29 (study day 37); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-27 (study day 66); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-27 (study day 157); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-19 (study day 180); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-09 (study day 262); relationship: Y

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-04 (study day 287); relationship: Y

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-24 (study day 307); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-03-12 (study day 386); relationship: Y

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-05-11 (study day 446); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.